NCT01017120 - A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne | Biotech Hunter

Enrollment

742

Participants

Timeline

Start Date

October 1, 2009

Primary Completion Date

November 1, 2010

Study Completion Date

November 9, 2010

Conditions

Acne Vulgaris

Interventions

DRUG

Tazarotene Foam

Tazarotene foam once a day application to the face

DRUG

Vehicle Foam

Vehicle Foam once a day application to the face

Trial Locations (18)

14623

Dermatology Associates of Rochester, PC, Rochester

23507

Virginia Clinical Research, Inc., Norfolk

30022

Atlanta Dermatology & Vein Research Center, PC, Alpharetta

30078

Gwinnett Clinical Research Center, Inc., Snellville

33175

FXM Research Corporation, Miami

40202

Dermatology Specialists, Louisville

47714

Hudson Dermatology, Evansville

48084

Somerset Skin Centre, Troy

48202

Henry Ford Medical Center, Detroit

68144

Skin Specialists, P.C., Omaha

77056

Suzanne Bruce and Associates, PA, Houston

78229

Progressive Clinical Research, San Antonio

90404

The Laser Institute for Dermatology, Santa Monica

02919

Clinical Partners, LLC, Johnston

V3R 6A7

Guildford Dermatology Specialist, Surrey

R3C 1R4

Dermadvances Research, Winnipeg

L3P 1A8

Lynderm Research, Inc., Markham

P1B3Z7

North Bay Dermatology Centre, North Bay